Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey.


Journal

Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459

Informations de publication

Date de publication:
06 2023
Historique:
received: 26 01 2023
accepted: 16 02 2023
revised: 06 02 2023
medline: 9 6 2023
pubmed: 7 3 2023
entrez: 6 3 2023
Statut: ppublish

Résumé

In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 patients received advanced cellular therapies, 2524 of which were CAR-T treatments, an additional 3245 received DLI. Changes compared to the previous year were CAR-T treatment (+35%), allogeneic HCT +5.4%, autologous HCT +3.9%, more pronounced in non-malignant disorders. Main indications for allogeneic HCT were myeloid malignancies 10,745 (58%), lymphoid malignancies 5127 (28%) and non-malignant disorders 2501 (13%). Main indications for autologous HCT were lymphoid malignancies 22,129 (90%) and solid tumors 1635 (7%). In allogeneic HCT, use of haploidentical donors decreased by -0.9% while use of unrelated and sibling donors increased by +4.3% and +9%. Cord blood HCT decreased by -5.8%. Pediatric HCT increased overall by +5.6% (+6.9% allogeneic and +1.6% autologous). Increase in the use of CAR-T was mainly restricted to high-income countries. The drop in HCT activity reported in 2020 partially recovered in 2021, the second year of the SARS-CoV-2 pandemic. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual EBMT report reflects current activities useful for health care resource planning.

Identifiants

pubmed: 36879108
doi: 10.1038/s41409-023-01943-3
pii: 10.1038/s41409-023-01943-3
pmc: PMC9987384
doi:

Substances chimiques

Receptors, Chimeric Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

647-658

Informations de copyright

© 2023. The Author(s).

Références

Bone Marrow Transplant. 2022 Aug;57(8):1217-1239
pubmed: 35589997
Bone Marrow Transplant. 2023 Jun;58(6):659-666
pubmed: 36894635
Bone Marrow Transplant. 1991 Sep;8(3):197-201
pubmed: 1958899
Stem Cells. 2010 Aug;28(8):1446-55
pubmed: 20597105
Bone Marrow Transplant. 2020 Nov;55(11):2071-2076
pubmed: 32404975
EMBO Mol Med. 2017 Sep;9(9):1183-1197
pubmed: 28765140
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385
pubmed: 30837712
Bone Marrow Transplant. 2020 Aug;55(8):1604-1613
pubmed: 32066864
Bone Marrow Transplant. 2016 Jun;51(6):786-92
pubmed: 26901709
Lancet Haematol. 2022 Oct;9(10):e786-e795
pubmed: 36174641
Bone Marrow Transplant. 2020 May;55(5):906-917
pubmed: 31740767
Eur J Immunol. 2015 Sep;45(9):2457-69
pubmed: 26202766
Br J Haematol. 2021 Feb;192(3):467-473
pubmed: 33474730
Bone Marrow Transplant. 2022 Feb;57(2):299-301
pubmed: 34802048
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643233
Bone Marrow Transplant. 2021 Jul;56(7):1493-1508
pubmed: 34031556
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Bone Marrow Transplant. 2017 Jun;52(6):811-817
pubmed: 28287639
Bone Marrow Transplant. 2015 Mar;50(3):321-3
pubmed: 25501349
JAMA. 2010 Apr 28;303(16):1617-24
pubmed: 20424252
Bone Marrow Transplant. 2018 Sep;53(9):1139-1148
pubmed: 29540849
Bone Marrow Transplant. 2022 May;57(5):742-752
pubmed: 35194156
Lancet Haematol. 2019 Nov;6(11):e573-e584
pubmed: 31477550
Leukemia. 2021 Dec;35(12):3444-3454
pubmed: 34725454
Blood. 2022 Mar 3;139(9):1330-1339
pubmed: 34570879
Bone Marrow Transplant. 2016 Jun;51(6):778-85
pubmed: 26901703
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Blood. 2021 Mar 11;137(10):1416-1423
pubmed: 33120429
Haematologica. 2010 Apr;95(4):637-43
pubmed: 20378578
Leukemia. 2021 Dec;35(12):3585-3588
pubmed: 34750508
N Engl J Med. 2007 Oct 11;357(15):1472-5
pubmed: 17928594
Blood Rev. 2019 Mar;34:34-44
pubmed: 30467067
Haematologica. 2020 Jan 31;105(2):297-316
pubmed: 31753925
Lancet Haematol. 2015 Mar;2(3):e91-100
pubmed: 26687803

Auteurs

Jakob R Passweg (JR)

EBMT Activity Survey Office, Hematology Division, University Hospital, Basel, Switzerland. jakob.passweg@usb.ch.

Helen Baldomero (H)

EBMT Activity Survey Office, Hematology Division, University Hospital, Basel, Switzerland.

Fabio Ciceri (F)

Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Selim Corbacioglu (S)

Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

Rafael de la Cámara (R)

Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain.

Harry Dolstra (H)

Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Bertram Glass (B)

Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany.

Raffaella Greco (R)

Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Donal P McLornan (DP)

Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.

Bénédicte Neven (B)

Pediatric Immune-hematology Unit, Necker Children Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.

Régis Peffault de Latour (RP)

BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.

Zinaida Perić (Z)

School of Medicine, University of Zagreb, University Hospital Center Zagreb, Zagreb, Croatia.

Annalisa Ruggeri (A)

Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

John A Snowden (JA)

Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Anna Sureda (A)

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH